1
|
Abid MB, Stromich J, Gundacker ND. Is ibrutinib associated with disseminated cryptococcosis with CNS involvement? Cancer Biol Ther 2018; 20:138-140. [PMID: 30148696 DOI: 10.1080/15384047.2018.1508622] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
Chronic lymphocytic leukemia (CLL) is a disorder of B cells that affects humoral as well as cell-mediated immunity. Protection against cryptococcal infections is mounted by an intricate and synchronized interplay of both integral arms of immunity. Whether CLL or small molecule tyrosine kinase inhibitors are independently predisposing hosts to cryptococcal infections remain to be explored. Herein, we present a report of a patient who developed disseminated cryptococcosis while receiving ibrutinib therapy for CLL in the salvage setting. We further present relevant literature available thus far on the topic and discuss immunologic mechanisms that may be involved in the fungal pathogenesis in such patients.
Collapse
Affiliation(s)
- Muhammad Bilal Abid
- a Division of Infectious Diseases , Medical College of Wisconsin , Milwaukee , WI , USA
| | - Jeremiah Stromich
- a Division of Infectious Diseases , Medical College of Wisconsin , Milwaukee , WI , USA
| | - Nathan D Gundacker
- a Division of Infectious Diseases , Medical College of Wisconsin , Milwaukee , WI , USA
| |
Collapse
|
2
|
Springuel L, Losdyck E, Saussoy P, Turcq B, Mahon FX, Knoops L, Renauld JC. Loss of mutL homolog-1 (MLH1) expression promotes acquisition of oncogenic and inhibitor-resistant point mutations in tyrosine kinases. Cell Mol Life Sci 2016; 73:4739-4748. [PMID: 27436342 PMCID: PMC11108519 DOI: 10.1007/s00018-016-2310-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2016] [Revised: 07/11/2016] [Accepted: 07/15/2016] [Indexed: 11/29/2022]
Abstract
Genomic instability drives cancer progression by promoting genetic abnormalities that allow for the multi-step clonal selection of cells with growth advantages. We previously reported that the IL-9-dependent TS1 cell line sequentially acquired activating substitutions in JAK1 and JAK3 upon successive selections for growth factor independent and JAK inhibitor-resistant cells, suggestive of a defect in mutation avoidance mechanisms. In the first part of this paper, we discovered that the gene encoding mutL homolog-1 (MLH1), a key component of the DNA mismatch repair system, is silenced by promoter methylation in TS1 cells. By means of stable ectopic expression and RNA interference methods, we showed that the high frequencies of growth factor-independent and inhibitor-resistant cells with activating JAK mutations can be attributed to the absence of MLH1 expression. In the second part of this paper, we confirm the clinical relevance of our findings by showing that chronic myeloid leukemia relapses upon ABL-targeted therapy correlated with a lower expression of MLH1 messenger RNA. Interestingly, the mutational profile observed in our TS1 model, characterized by a strong predominance of T:A>C:G transitions, was identical to the one described in the literature for primitive cells derived from chronic myeloid leukemia patients. Taken together, our observations demonstrate for the first time a causal relationship between MLH1-deficiency and incidence of oncogenic point mutations in tyrosine kinases driving cell transformation and acquired resistance to kinase-targeted cancer therapies.
Collapse
MESH Headings
- Animals
- Cell Line
- Clone Cells
- DNA Methylation/drug effects
- DNA Methylation/genetics
- Down-Regulation/drug effects
- Drug Resistance, Neoplasm/drug effects
- Drug Resistance, Neoplasm/genetics
- Gene Expression Regulation, Leukemic/drug effects
- Gene Knockdown Techniques
- Humans
- Intercellular Signaling Peptides and Proteins/pharmacology
- Janus Kinases/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Mice
- MutL Protein Homolog 1/genetics
- MutL Protein Homolog 1/metabolism
- Oncogenes
- Point Mutation/genetics
- Promoter Regions, Genetic/genetics
- Protein Kinase Inhibitors/pharmacology
- RNA, Small Interfering/metabolism
Collapse
Affiliation(s)
- Lorraine Springuel
- Ludwig Institute for Cancer Research, Brussels Branch, Avenue Hippocrate 74, 1200, Brussels, Belgium
- de Duve Institute, Université Catholique de Louvain, Brussels, Belgium
| | - Elisabeth Losdyck
- Ludwig Institute for Cancer Research, Brussels Branch, Avenue Hippocrate 74, 1200, Brussels, Belgium
- de Duve Institute, Université Catholique de Louvain, Brussels, Belgium
| | - Pascale Saussoy
- Hematology Unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Béatrice Turcq
- Leukemic Hematopoiesis and Therapeutic Targets Laboratory, University of Bordeaux, Bordeaux, France
| | - François-Xavier Mahon
- Leukemic Hematopoiesis and Therapeutic Targets Laboratory, University of Bordeaux, Bordeaux, France
| | - Laurent Knoops
- Ludwig Institute for Cancer Research, Brussels Branch, Avenue Hippocrate 74, 1200, Brussels, Belgium.
- de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.
- Hematology Unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
| | - Jean-Christophe Renauld
- Ludwig Institute for Cancer Research, Brussels Branch, Avenue Hippocrate 74, 1200, Brussels, Belgium.
- de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.
| |
Collapse
|
3
|
Soverini S, De Benedittis C, Papayannidis C, Polakova KM, Venturi C, Russo D, Bresciani P, Iurlo A, Mancini M, Vitale A, Chiaretti S, Foà R, Abruzzese E, Sorà F, Kohlmann A, Haferlach T, Baccarani M, Cavo M, Martinelli G. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. Leukemia 2016; 30:1615-9. [DOI: 10.1038/leu.2016.17] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
4
|
Burchert A. Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence. Curr Hematol Malig Rep 2014; 9:9-16. [PMID: 24500518 PMCID: PMC3930845 DOI: 10.1007/s11899-013-0196-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Deregulated BCR-ABL oncogenic activity leads to transformation, oncogene addiction and drives disease progression in chronic myeloid leukemia (CML). Inhibition of BCR-ABL using Abl-specific kinase inhibitors (TKI) such as imatinib induces remarkable clinical responses. However, approximately only less than 15 % of all chronic-phase CML patients will remain relapse-free after discontinuation of imatinib in deep molecular remission. It is not well understood why persisting CML cells survive under TKI therapy without developing clonal evolution and frank TKI resistance. BCR-ABL expression level may be critically involved. Whereas higher BCR-ABL expression has been described as a pre-requisite for malignant CML stem cell transformation and CML progression to blast crisis, recent evidence suggests that during persistence TKI select for CML precursors with low BCR-ABL expression. Genetic, translational and clinical evidence is discussed to suggest that TKI-induced maintenance of low BCR-ABL signaling output may be potently tumor suppressive, because it abrogates oncogenic addiction.
Collapse
Affiliation(s)
- Andreas Burchert
- Hematology, Oncology and Immunology, Philipps University Marburg, University Hospital Gießen and Marburg (UKGM), Campus Marburg, 35043, Marburg, Germany,
| |
Collapse
|
5
|
BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability. Leukemia 2012; 27:629-34. [PMID: 23047475 DOI: 10.1038/leu.2012.294] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia in chronic phase (CML-CP). Unfortunately, 25% of TKI-naive patients and 50-90% of patients developing TKI-resistance carry CML clones expressing TKI-resistant BCR-ABL1 kinase mutants. We reported that CML-CP leukemia stem and progenitor cell populations accumulate high amounts of reactive oxygen species, which may result in accumulation of uracil derivatives in genomic DNA. Unfaithful and/or inefficient repair of these lesions generates TKI-resistant point mutations in BCR-ABL1 kinase. Using an array of specific substrates and inhibitors/blocking antibodies we found that uracil DNA glycosylase UNG2 were inhibited in BCR-ABL1-transformed cell lines and CD34(+) CML cells. The inhibitory effect was not accompanied by downregulation of nuclear expression and/or chromatin association of UNG2. The effect was BCR-ABL1 kinase-specific because several other fusion tyrosine kinases did not reduce UNG2 activity. Using UNG2-specific inhibitor UGI, we found that reduction of UNG2 activity increased the number of uracil derivatives in genomic DNA detected by modified comet assay and facilitated accumulation of ouabain-resistant point mutations in reporter gene Na(+)/K(+)ATPase. In conclusion, we postulate that BCR-ABL1 kinase-mediated inhibition of UNG2 contributes to accumulation of point mutations responsible for TKI resistance causing the disease relapse, and perhaps also other point mutations facilitating malignant progression of CML.
Collapse
|
6
|
JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms. Adv Hematol 2012; 2012:535709. [PMID: 22400031 PMCID: PMC3286888 DOI: 10.1155/2012/535709] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2011] [Revised: 11/29/2011] [Accepted: 12/04/2011] [Indexed: 01/17/2023] Open
Abstract
JAK2 is a tyrosine kinase gene that plays an essential role in the development of normal haematopoiesis. Hyperactivation of JAK2 occurs in myeloproliferative neoplasms by different mechanisms. As a consequence, JAK2 inhibitors have been designed to suppress the cytokine signalling cascade caused by the constitutive activation of JAK2. In clinical trials, JAK2 inhibitors are efficient in decreasing spleen size, controlling clinical symptoms, and improving quality of life in patients with myeloproliferative neoplasms. However, JAK2 inhibitors are unable to target uncommitted hematopoietic progenitors responsible of the initiation of the myeloproliferative disease. It is expected that, in order to cure the myeloproliferative disease, JAK2 inhibitors should be combined with other drugs to target simultaneously different pathways and to target the initiator hematopoietic cell population in myeloproliferative disorders. Taking advantage of the inhibition of the cytokine cascade of JAK2 inhibitors, these compounds are going to be used not only to treat patients with hematological neoplasms but may also be beneficial to treat patients with rheumatoid arthritis or other inflammatory diseases.
Collapse
|
7
|
Wongboonma W, Thongnoppakhun W, Auewarakul CU. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients. Exp Mol Pathol 2012; 92:259-65. [PMID: 22314255 DOI: 10.1016/j.yexmp.2012.01.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2011] [Revised: 01/17/2012] [Accepted: 01/19/2012] [Indexed: 11/15/2022]
Abstract
BCR-ABL kinase domain (KD) mutation is the main mechanism associated with resistance to tyrosine kinase inhibitors (TKI) in chronic myeloid leukemia (CML) patients. This study targeted a large cohort of CML (n=171) comprising 80 naïve CML cases without prior TKI exposure as well as 91 cases undergoing 1st generation (imatinib) and/or 2nd generation (nilotinib/dasatinib) TKI therapy. KD mutations were analyzed by denaturing high performance liquid chromatography followed by direct sequencing. Twenty-one types of mutations were found in 37 patients including 13 known mutations and 8 previously unidentified mutations. Thirty cases had a single mutation while 7 cases had multiple mutations. Twenty-three percent of patients receiving first-line imatinib, 69% of imatinib-resistant patients receiving 2nd generation TKI, and 75% of advanced phase patients treated with front-line 2nd generation TKI had KD mutations. Interestingly, 9% of TKI-naïve CML cases were also discovered to carry the KD mutations including 5 novel variants. Patients who received hydroxyurea had a 2-fold increase in KD mutations as compared to newly diagnosed patients but they still had a lower mutation frequency than TKI-exposed cases. Mutations in the naïve cases were mainly localized in the C-helix domain and SH3 contact site whereas in exposed cases predominantly in the drug contact site, P-loop, and catalytic domain. T315I resistant mutation was identified only in TKI-exposed cases. In conclusion, several known and novel BCR-ABL KD mutations were discovered in the TKI-naïve and -exposed Southeast Asian CML patients, supporting the concept that naturally occurring KD mutations were present in leukemic cells prior to drug exposure. T315I resistant mutation was completely undetectable in this naïve Southeast Asian cohort; its incidence, however, increases with drug exposure.
Collapse
Affiliation(s)
- Wanwisa Wongboonma
- Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | | | | |
Collapse
|